Inhaler trial aims to fight fatal lung scarring disease
NCT ID NCT06968845
Summary
This study is testing an experimental inhaled medicine called LTI-03 for people with Idiopathic Pulmonary Fibrosis (IPF), a serious disease that causes progressive lung scarring. About 120 participants will use an inhaler with either LTI-03 or a placebo for 24 weeks to see if the drug is safe and if it can slow lung scarring or improve symptoms. The goal is to find a new treatment to help control this difficult disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
El Paso Pulmonary Association
RECRUITINGEl Paso, Texas, 79902, United States
Contact
Contact Email: •••••@•••••
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Contact
-
Paradigm Clinical Research Centers, LLC
RECRUITINGSan Diego, California, 92108, United States
Contact Email: •••••@•••••
Contact
-
The Lung Research Center, LLC
RECRUITINGChesterfield, Missouri, 63017, United States
Contact Email: •••••@•••••
Contact
-
UAB Lung Health Center
RECRUITINGBirmingham, Alabama, 35233, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.